Suppr超能文献

接受阿片类药物/对乙酰氨基酚复方处方止痛药治疗的患者发生与肝毒性相关的住院风险。

Risk of hepatotoxicity-related hospitalizations among patients treated with opioid/acetaminophen combination prescription pain medications.

机构信息

Analysis Group, Inc., Boston, Massachusetts 02199, USA.

出版信息

Pain Med. 2010 Nov;11(11):1718-25. doi: 10.1111/j.1526-4637.2010.00979.x.

Abstract

OBJECTIVE

This study determined the risk of serious hepatotoxicity resulting in hospitalizations among patients prescribed opioid/acetaminophen combinations.

METHODS

A retrospective cohort study using an insurance claims database was conducted. Adult patients with ≥1 claim for oxycodone/acetaminophen or hydrocodone/acetaminophen combinations were included (N = 1,228,356). A pre-post design was employed to compare serious hepatotoxicity risk before versus after initiation of opioid/acetaminophen combination. Serious hepatotoxicity risk between the opioid/acetaminophen group and a control group of opioid-alone users (N = 11,809) was also examined. Within the opioid/acetaminophen group, risk of hepatotoxicity-related hospitalizations pre- versus post-opioid/acetaminophen treatment was compared using the normal approximation with the binomial distribution. The incidence rate of hepatotoxicity-related hospitalizations for the opioid/acetaminophen group was compared with the opioid-alone group using multivariate Poisson regression adjusting for baseline differences between groups.

RESULTS

Of the opioid/acetaminophen cohort, hepatotoxicity-related hospitalization risk in the 6-month post-opioid/acetaminophen period was lower than that in the pre-period with a risk reduction of 1.2 per 10,000 (pre-period = 0.12%; 95% confidence interval [CI], 0.12 to 0.13; post-period = 0.11%; 95% CI, 0.11 to 0.12). In the 12-month period, risk increased in the post-period by 2.4 per 10,000 (pre-period = 0.14%; 95% CI, 0.14 to 0.15; post-period = 0.17%; 95% CI, 0.16 to 0.18). After adjusting for confounders, the opioid-alone group did not demonstrate a lower rate of hepatotoxicity-related hospitalizations than the opioid/acetaminophen group (incidence rate ratio of opioid-alone over opioid/acetaminophen = 2.9; 95% CI, 1.8 to 4.7).

CONCLUSIONS

There is no population data-based evidence supporting elevated risk of hepatotoxicity-related hospitalization associated with opioid/acetaminophen combinations.

摘要

目的

本研究旨在确定处方阿片类药物/对乙酰氨基酚复方制剂的患者发生严重肝毒性导致住院的风险。

方法

采用保险索赔数据库进行回顾性队列研究。纳入至少有 1 次羟考酮/对乙酰氨基酚或氢可酮/对乙酰氨基酚复方制剂用药索赔的成年患者(N=1228356)。采用前后设计比较阿片类药物/对乙酰氨基酚复方制剂起始前后严重肝毒性风险。还比较了阿片类药物/对乙酰氨基酚组与阿片类药物单一用药者(N=11809)的对照组之间的严重肝毒性风险。在阿片类药物/对乙酰氨基酚组中,使用二项分布的正态近似法比较了阿片类药物/对乙酰氨基酚治疗前后肝毒性相关住院的风险。使用多变量泊松回归调整组间基线差异,比较了阿片类药物/对乙酰氨基酚组与阿片类药物单一用药组的肝毒性相关住院发生率。

结果

在阿片类药物/对乙酰氨基酚队列中,阿片类药物/对乙酰氨基酚治疗后 6 个月的肝毒性相关住院风险低于治疗前,风险降低了 1.2/10000(治疗前为 0.12%;95%置信区间[CI],0.12 至 0.13;治疗后为 0.11%;95%CI,0.11 至 0.12)。在 12 个月期间,治疗后 12 个月的风险增加了 2.4/10000(治疗前为 0.14%;95%CI,0.14 至 0.15;治疗后为 0.17%;95%CI,0.16 至 0.18)。调整混杂因素后,阿片类药物单一用药组的肝毒性相关住院率并不低于阿片类药物/对乙酰氨基酚组(阿片类药物单一用药相对于阿片类药物/对乙酰氨基酚的发生率比为 2.9;95%CI,1.8 至 4.7)。

结论

没有基于人群数据的证据支持阿片类药物/对乙酰氨基酚复方制剂与肝毒性相关住院风险升高相关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验